RecruitingPhase 4NCT03218137

Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions


Sponsor

Weill Medical College of Cornell University

Enrollment

100 participants

Start Date

Feb 13, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and/or verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

  • Diagnosis of premature ventricular contractions (PVCs)
  • Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs
  • Male or female between the ages of 18 and 70 years
  • Capable of giving informed consent

Exclusion Criteria5

  • Any structural heart disease
  • Coronary artery disease (≥ 70% stenosis)
  • Current treatment with anti-arrhythmic drugs
  • Pregnant
  • Asthma (if administering adenosine)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdenosine

Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg


Locations(1)

Weill Cornell Medicine

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03218137


Related Trials